---
layout: post
title: "Determination of Regulatory Review Period for Purposes of Patent Extension; PREVYMIS IV Solution, New Drug Application 209940"
date: 2026-02-05 19:01:30 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-24719
original_published: 2022-11-14 00:00:00 +0000
significance: 8.00
---

# Determination of Regulatory Review Period for Purposes of Patent Extension; PREVYMIS IV Solution, New Drug Application 209940

**Published:** February 05, 2026 19:01 UTC
**Source:** Federal Register
**Original Published:** November 14, 2022 00:00 UTC
**Document Number:** 2022-24719

## Summary

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PREVYMIS IV Solution, new drug application (NDA) 209940, and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/11/14/2022-24719/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prevymis-iv-solution-new)
- API: https://www.federalregister.gov/api/v1/documents/2022-24719

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
